HRP20211046T1 - Upotreba derivata benzimidazola kod noćnog proboja kiseline - Google Patents
Upotreba derivata benzimidazola kod noćnog proboja kiseline Download PDFInfo
- Publication number
- HRP20211046T1 HRP20211046T1 HRP20211046TT HRP20211046T HRP20211046T1 HR P20211046 T1 HRP20211046 T1 HR P20211046T1 HR P20211046T T HRP20211046T T HR P20211046TT HR P20211046 T HRP20211046 T HR P20211046T HR P20211046 T1 HRP20211046 T1 HR P20211046T1
- Authority
- HR
- Croatia
- Prior art keywords
- dosage form
- unit dosage
- accordance
- intended
- form intended
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Solid-Sorbent Or Filter-Aiding Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Claims (11)
1. Farmaceutski pripravak namijenjen upotrebi u sprječavanju ili liječenju noćnog proboja kiseline, naznačen time što sadrži:
spoj kojeg prikazuje kemijska formula 1, niže, ili njegovu farmaceutski prihvatljivu sol, kao aktivni sastojak
[image]
.
2. Farmaceutski pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1,
naznačen time što pripravak sadrži 50 mg do 200 mg spoja kojeg prikazuje kemijska formula 1, iznad, ili njegovu farmaceutski prihvatljivu sol.
3. Jedinični oblik doziranja namijenjen upotrebi u sprječavanju ili liječenju noćnog proboja kiseline, naznačen time što sadrži:
50 mg do 200 mg spoja kojeg prikazuje kemijska formula 1, niže, ili njegovu farmaceutski prihvatljivu sol
[image]
.
4. Jedinični oblik doziranja namijenjen upotrebi u skladu s patentnim zahtjevom 3, naznačen time što dodatno sadrži: farmaceutski prihvatljivi nosač.
5. Jedinični oblik doziranja namijenjen upotrebi u skladu s patentnim zahtjevom 3,
naznačen time što se jedinični oblik doziranja primjenjuje na pacijentu koji boluje od bolest koju se bira iz skupine koju čine bolest erozivnog gastroezofagealnog refluksa (GERD), bolest neerozivnog gastroezofagealnog refluksa (NERD), želučani vrijed, Barrettov jednjak, te poremećaj motiliteta jednjaka.
6. Jedinični oblik doziranja namijenjen upotrebi u skladu s patentnim zahtjevom 3,
naznačen time što jedinični oblik doziranja olakšava ili ublažava simptomi žgaravice.
7. Jedinični oblik doziranja namijenjen upotrebi u skladu s patentnim zahtjevom 3,
naznačen time što se jedinični oblik doziranja primjenjuje prije večere ili spavanja.
8. Jedinični oblik doziranja namijenjen upotrebi u skladu s patentnim zahtjevom 3,
naznačen time što se jedinični oblik doziranja primjenjuje jedan do tri puta dnevno do najmanje prihvatljive dnevne doze.
9. Jedinični oblik doziranja namijenjen upotrebi u skladu s patentnim zahtjevom 3,
naznačen time što je jedinični oblik doziranja jedinični oblik doziranja namijenjen oralnoj primjeni.
10. Jedinični oblik doziranja namijenjen upotrebi u skladu s patentnim zahtjevom 3,
naznačen time što je postotak vremena u kojem želučani pH se održava na 4 ili višem od 12 sata nakon primjene jediničnog oblika doziranja 65% ili više.
11. Jedinični oblik doziranja namijenjen upotrebi u skladu s patentnim zahtjevom 3,
naznačen time što želučani pH doseže 4 unutar 2 sata nakon primjene jediničnog oblika doziranja.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562172680P | 2015-06-08 | 2015-06-08 | |
| PCT/KR2016/006072 WO2016200148A1 (ko) | 2015-06-08 | 2016-06-08 | 야간 산 분비에 대한 벤즈이미다졸 유도체의 용도 |
| EP16807788.1A EP3305291B1 (en) | 2015-06-08 | 2016-06-08 | Uses of benzimidazole derivative for nocturnal acid breakthrough |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211046T1 true HRP20211046T1 (hr) | 2021-10-01 |
Family
ID=57504150
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211046TT HRP20211046T1 (hr) | 2015-06-08 | 2016-06-08 | Upotreba derivata benzimidazola kod noćnog proboja kiseline |
Country Status (27)
| Country | Link |
|---|---|
| US (2) | US10512635B2 (hr) |
| EP (1) | EP3305291B1 (hr) |
| JP (1) | JP6792269B2 (hr) |
| KR (3) | KR20160144927A (hr) |
| CN (2) | CN108012527A (hr) |
| CL (1) | CL2017003133A1 (hr) |
| CY (1) | CY1124590T1 (hr) |
| DK (1) | DK3305291T3 (hr) |
| ES (1) | ES2890481T3 (hr) |
| HK (1) | HK1252562A1 (hr) |
| HR (1) | HRP20211046T1 (hr) |
| HU (1) | HUE056322T2 (hr) |
| IL (1) | IL256127B (hr) |
| LT (1) | LT3305291T (hr) |
| MA (1) | MA41730B1 (hr) |
| MX (1) | MX374972B (hr) |
| MY (1) | MY197209A (hr) |
| PH (1) | PH12017502221A1 (hr) |
| PL (1) | PL3305291T3 (hr) |
| PT (1) | PT3305291T (hr) |
| RS (1) | RS62074B1 (hr) |
| RU (1) | RU2672248C1 (hr) |
| SG (1) | SG11201710006PA (hr) |
| SI (1) | SI3305291T1 (hr) |
| SM (1) | SMT202100399T1 (hr) |
| TN (1) | TN2017000510A1 (hr) |
| WO (1) | WO2016200148A1 (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101960357B1 (ko) * | 2016-12-26 | 2019-03-20 | 씨제이헬스케어 주식회사 | 벤즈이미다졸 유도체를 포함하는 신규한 제제 |
| KR102262743B1 (ko) | 2017-07-07 | 2021-06-09 | 에이치케이이노엔 주식회사 | 주사용 조성물 |
| LT3843723T (lt) * | 2018-08-29 | 2026-03-25 | Hk Inno.N Corporation | Kompozicija, skirta išnaikinti helicobacter pylori |
| PL3927340T3 (pl) * | 2019-02-18 | 2026-03-09 | Hk Inno.N Corporation | Kompozycja farmaceutyczna zawierająca tegoprazan do zapobiegania nawrotowi choroby refluksowej przełyku |
| UY39094A (es) * | 2020-02-27 | 2021-07-30 | Hk Inno N Corp | Composición farmacéutica que comprende compuesto derivado de bencimidazol |
| US10991185B1 (en) | 2020-07-20 | 2021-04-27 | Abbott Laboratories | Digital pass verification systems and methods |
| WO2022086238A1 (en) * | 2020-10-23 | 2022-04-28 | Hk Inno.N Corporation | Orally disintegrating tablet comprising benzimidazole derivative compound and preparation method thereof |
| WO2023106841A1 (ko) * | 2021-12-08 | 2023-06-15 | (주) 팜젠사이언스 | 벤즈이미다졸 유도체 화합물 및 이의 용도 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR043063A1 (es) * | 2002-12-13 | 2005-07-13 | Altana Pharma Ag | Bencimidazoles 6-sustituidos y su uso como inhibidores de secreciones gastricas |
| WO2005020954A2 (en) * | 2003-09-03 | 2005-03-10 | Agi Therapeutics Limited | Proton pump inhibitor formulations, and methods of preparing and using such formulations |
| DE602006009105D1 (de) | 2005-06-14 | 2009-10-22 | Raqualia Pharma Inc | Chroman-substituierte benzimidazolderivate als säurepumpenantagonisten |
| KR101088247B1 (ko) | 2005-12-19 | 2011-11-30 | 라퀄리아 파마 인코포레이티드 | 크로메인 치환된 벤즈이미다졸 및 이들의 산 펌프억제제로서의 용도 |
| EP2068841B1 (en) | 2006-10-05 | 2018-09-26 | Santarus, Inc. | Novel formulations of proton pump inhibitors and methods of using these formulations |
| WO2008151927A2 (en) | 2007-06-15 | 2008-12-18 | Nycomed Gmbh | 6-n-substituted benz imidazole derivatives as acid pump antagonists |
| EA017064B1 (ru) | 2008-03-10 | 2012-09-28 | Такеда Фармасьютикал Компани Лимитед | Кристаллическое производное бензимидазола |
| KR101605063B1 (ko) | 2009-07-09 | 2016-03-21 | 라퀄리아 파마 인코포레이티드 | 소화관 운동이상이 관여하는 질환의 치료용 산 펌프 길항제 |
| CN102140099A (zh) | 2010-02-02 | 2011-08-03 | 山东轩竹医药科技有限公司 | 新的吡啶衍生物 |
| RU2537140C1 (ru) * | 2013-09-17 | 2014-12-27 | Леонид Федосеевич Ляпустин | Способ антихеликобактерной терапии желудка и двенадцатиперстной кишки |
-
2016
- 2016-06-08 HU HUE16807788A patent/HUE056322T2/hu unknown
- 2016-06-08 PT PT168077881T patent/PT3305291T/pt unknown
- 2016-06-08 ES ES16807788T patent/ES2890481T3/es active Active
- 2016-06-08 MX MX2017015926A patent/MX374972B/es active IP Right Grant
- 2016-06-08 LT LTEP16807788.1T patent/LT3305291T/lt unknown
- 2016-06-08 MA MA41730A patent/MA41730B1/fr unknown
- 2016-06-08 MY MYPI2017704650A patent/MY197209A/en unknown
- 2016-06-08 KR KR1020160071275A patent/KR20160144927A/ko not_active Ceased
- 2016-06-08 PL PL16807788T patent/PL3305291T3/pl unknown
- 2016-06-08 JP JP2017563939A patent/JP6792269B2/ja active Active
- 2016-06-08 EP EP16807788.1A patent/EP3305291B1/en active Active
- 2016-06-08 TN TNP/2017/000510A patent/TN2017000510A1/en unknown
- 2016-06-08 US US15/580,850 patent/US10512635B2/en active Active
- 2016-06-08 RU RU2017144552A patent/RU2672248C1/ru active
- 2016-06-08 SI SI201631260T patent/SI3305291T1/sl unknown
- 2016-06-08 SG SG11201710006PA patent/SG11201710006PA/en unknown
- 2016-06-08 HK HK18111875.7A patent/HK1252562A1/zh unknown
- 2016-06-08 CN CN201680033581.6A patent/CN108012527A/zh active Pending
- 2016-06-08 RS RS20210848A patent/RS62074B1/sr unknown
- 2016-06-08 SM SM20210399T patent/SMT202100399T1/it unknown
- 2016-06-08 DK DK16807788.1T patent/DK3305291T3/da active
- 2016-06-08 WO PCT/KR2016/006072 patent/WO2016200148A1/ko not_active Ceased
- 2016-06-08 CN CN202410477736.1A patent/CN118557572A/zh active Pending
- 2016-06-08 HR HRP20211046TT patent/HRP20211046T1/hr unknown
-
2017
- 2017-12-05 PH PH12017502221A patent/PH12017502221A1/en unknown
- 2017-12-05 IL IL256127A patent/IL256127B/en active IP Right Grant
- 2017-12-07 CL CL2017003133A patent/CL2017003133A1/es unknown
-
2018
- 2018-03-26 KR KR1020180034581A patent/KR102061052B1/ko active Active
-
2019
- 2019-11-07 US US16/676,659 patent/US11033532B2/en active Active
- 2019-12-20 KR KR1020190172242A patent/KR20200002739A/ko not_active Withdrawn
-
2021
- 2021-06-30 CY CY20211100582T patent/CY1124590T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211046T1 (hr) | Upotreba derivata benzimidazola kod noćnog proboja kiseline | |
| HRP20200665T1 (hr) | Bifenilsulfonamidni antagonist receptora za endotelin i angiotenzin ii za liječenje glomeruloskleroze i iga-inducirane nefropatije | |
| CY1119886T1 (el) | Μεθοδος βιομηχανικης κατασκευης μιας φαρμακευτικης συνθεσης στην μορφη δισκιων παρατεταμενης απελευθερωσης που περιεχουν πιρφενιδονη και χρηση αυτων στην υποστροφη χρονιας νεφρικης ανεπαρκειας, καψικης συσπασης μαστου και ηπατικης ινωσης σε ανθρωπους | |
| HK1221646A1 (zh) | 高剂量普利多匹定用於治疗亨廷顿舞蹈症的用途 | |
| HRP20160189T1 (hr) | Liječenje crohnove bolesti lakvinimodom | |
| BR112013032122A2 (pt) | liberação modificada de 4-metil-3-[[4-(3-piridinil)-2-pirimidinil]amino]-n-[5-(4-metil-1h-imidazol-1-il)-3-(trifluorometil)fenil] benzamida solubilizada usando ácidos orgânicos | |
| HRP20180425T1 (hr) | Čvrste kompozicije koje sadrže agonist glp-1 i sol n-(8-(2-hidroksibenzoil)amino)kaprilne kiseline | |
| EA201290026A1 (ru) | Способ лечения пациента, имеющего риск развития язвы, связанной с приемом нестероидных противовоспалительных средств (nsaid) | |
| JP2015057451A5 (hr) | ||
| JP2013520405A5 (hr) | ||
| JP2015529234A5 (hr) | ||
| HRP20201316T1 (hr) | Novi modulatori receptora sfingozin-fosfata | |
| SI2582683T1 (en) | Treatment of gout and hyperuricemia | |
| ME02474B (me) | Terapijski režimi | |
| HRP20171742T4 (hr) | 2,4,6-trifluor-n-[6-(1-metilpiperidin-4-karbonil)piridin-2-il]benzamid, namijenjen liječenju migrene oralnom ili intravenskom primjenom | |
| NZ700924A (en) | Dosage regimen for a pi-3 kinase inhibitor | |
| HK1208222A1 (en) | Modified release formulations for oprozomib | |
| JP2019218379A5 (hr) | ||
| EA200901146A1 (ru) | Твердые лекарственные формы, содержащие алискирен и его фармацевтически приемлемые соли | |
| JP2017526693A5 (hr) | ||
| JP2014527506A5 (hr) | ||
| HRP20250002T1 (hr) | Ampreloksetin, namijenjen upotrebi u liječenju neurogene ortostatske hipotenzije | |
| RU2018119085A (ru) | Схема введения ингибитора фосфатидилинозитол-3-киназы | |
| HRP20190211T1 (hr) | Inhibitor proteina za prijenos kolesterilestera (cetp) i farmaceutski pripravci koji sadrže spomenuti inhibitor za primjenu u liječenju ili prevenciji kardiovaskularnih bolesti | |
| HRP20161796T1 (hr) | Farmaceutski pripravak za primjenu u tretmanu ili prevenciji deficijencije vitamina i minerala kod pacijenata podvrgnutih operaciji želučane premosnice |